**Q9554:** E. A. L. Wozniak, et al. Cholecystokinin 1 Receptor (Cck1R) Activates mTORC1 signaling and is Protective to. BioRxiv 2021.

- **Agents:** A71623
- **Vehicle:** PBS
- **Route:** IP
- **Species:** Mice
- **Pump:** 1004
- **Duration:** 31 weeks

**ALZET Comments:** Dose (0.02 mg/kg/day); Controls received mp w/ vehicle; animal info (5 week old mice); behavioral testing (Rotarod; Beam Walk); pumps replaced every 7 weeks; neurodegenerative (Purkinje neuron degeneration);


- **Agents:** Olmesartan, Hydralazine Hydrochloride
- **Vehicle:** Saline
- **Route:** SC
- **Species:** Rat
- **Pump:** 2ML2
- **Duration:** 26 weeks

**ALZET Comments:** Dose (Olmesartan- 3 mg/kg/day or Hydralazine Hydrochloride- 10 mg/kg/day); Controls received mp w/ vehicle; animal info (); pumps replaced every 2 weeks; long-term study; Blood pressure measured via Tail Cuff Method ;


- **Agents:** L655,708;  (R)-4-ACPBPA; (S)-4-ACPBPA
- **Vehicle:** DMSO; Saline
- **Route:** Not Stated
- **Species:** Mice
- **Pump:** 1002
- **Duration:** 4 weeks

**ALZET Comments:** Dose (200 ug/kg/day); 0.9% Saline used; Controls received mp w/ vehicle; animal info (male C57BL/6J mice, 2-3 months old, 27-30 g); behavioral testing (Grid-Walking test; Cylinder task); pumps replaced every 2 weeks; ischemia (Ischemic stroke);

**Q9505:** T. Troiano, et al. Inhibition of NOX1 mitigates blood pressure increases in elastin insufficiency. American Physiological Society 2021;

- **Agents:** Apocynin
- **Vehicle:** DMSO; Route: SC
- **Species:** Mice
- **Pump:** 1004
- **Duration:** 56 days

**ALZET Comments:** Dose (10 mg/kg/day); 50% DMSO used; Controls received mp w/ vehicle; animal info (4–6 wk of age, male Eln+/+ and Eln+-/ mice); functionality of mp verified by residual volume; pumps replaced every 28 days; Blood pressure measured via angiocatheter;cardiovascular;


- **Agents:** Polyethylene, ultra high molecular mass weight; Interleukin-4, mouse recombinant
- **Vehicle:** BSA; PBS
- **Route:** SC
- **Species:** Mice
- **Pump:** Not Stated
- **Duration:** 8 weeks

**ALZET Comments:** Dose (15 mg/ml ultra high molecular mass weight polyethylene; 10 ug/ml Interleukin-4); 1% BSA-PBS used; Controls received mp w/ vehicle; animal info (male BALB/cByJ mice, 10-12 weeks); post op. care (buprenorphine); functionality of mp verified by residual volume; pumps replaced every 28 weeks; ultra high molecular mass weight polyethylene aka UHMWPE; mouse recombinant interleukin-4 aka IL-4; dependence;

**Q9358:** S. Maeda, et al. Notch signaling-modified mesenchymal stem cells improve tissue perfusion by induction of arteriogenesis in a rat hindlimb ischemia model. Scientific Reports 2021;11(1):2543

- **Agents:** Cyclosporin
- **Vehicle:** Not Stated
- **Route:** SC
- **Species:** Rat
- **Pump:** Not Stated
- **Duration:** 28 days

**ALZET Comments:** Dose (10 mg/kg/day); animal info (Female Sprague–Dawley rats, 10 weeks old); pumps replaced every 2 weeks; ischemia (rat handlimb ischemia model);

**Q9228:** N. D. Fried, et al. Angiotensin II type 1 receptor mediates pulmonary hypertension and right ventricular remodeling induced by inhaled nicotine. American Journal of Physiology Heart Circulatory Physiology 2021;320(4):H1526-H1534

- **Agents:** Losartan
- **Vehicle:** Saline
- **Route:** SC
- **Species:** Mice
- **Pump:** 1004
- **Duration:** 8 weeks

**ALZET Comments:** Dose (6.5, 5.0 mg/kg/day); Controls received mp w/ vehicle; animal info (Adult, male C57BL6/J mice, 8 to 12 weeks old, 23 to 30 g); post op. care (buprenorphine); pumps replaced every 4 weeks; cardiovascular;

**Agents:** SMO; LFPRLR SMO, mice; LFPRLR SMO, human  
**Vehicle:** Not Stated;  
**Route:** Not Stated;  
**Species:** Mice;  
**Pump:** 2004;  
**Duration:** 28 days;  
**ALZET Comments:** Dose: (100 pmoles/h); Controls received mp w/ vehicle; animal info: 8-week old Foxp3+EGFP Balb/c or NOD-SCID mice; pumps replaced (as needed); SMO aka splice modulating oligomer; LFPRLR aka long form prolactin receptor; cancer (Breast cancer);

Q9169: S. L. Burke, et al. Role of Mineralocorticoid and Angiotensin Type 1 Receptors in the Paraventricular Nucleus in Angiotensin-Induced Hypertension. Frontiers in Physiology 2021;12(640373

**Agents:** Angiotensin II  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Rabbit;  
**Pump:** 2ML4;  
**Duration:** 12 weeks;  
**ALZET Comments:** Dose (24 ng/kg/min); 0.9% NaCl used; Controls received mp w/ vehicle; animal info (male New Zealand White rabbits, 2.3-3.1 kg); pumps replaced every 4 weeks; Angiotensin II aka AngII; cardiovascular;


**Agents:** Tacrolimus  
**Vehicle:** Not Stated;  
**Route:** SC;  
**Species:** Mice;  
**Pump:** 1002;  
**Duration:** 15 days;  
**ALZET Comments:** Dose (1.5 mg/kg body weight); animal info (Adult male BALB/c mice (6–7 weeks old, 17–22 g)); pumps replaced every 13 days; immunology;


**Agents:** Angiotensin II  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Mice;  
**Pump:** 2004;  
**Duration:** 8 weeks;  
**ALZET Comments:** Dose (700 ng/kg/min); Controls received mp w/ vehicle; animal info (8 weeks old, Male); pumps replaced every 4 weeks; cardiovascular;


**Agents:** Elamipretide  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Mice;  
**Pump:** Not Stated;  
**Duration:** 8 weeks;  
**ALZET Comments:** Dose (3 mg/kg/day); Controls received mp w/ vehicle; animal info (Male, C57BL/6, 24 months old); pumps replaced every 4 weeks; as Elamipretide aka SS-31 aka synthetic tetrapeptide; peptides; cardiovascular;


**Agents:** T140; AMD3100; TN14003  
**Vehicle:** PBS;  
**Route:** SC;  
**Species:** Pig;  
**Pump:** Not Stated;  
**Duration:** 12 weeks;  
**ALZET Comments:** Dose (180 ug/ml); Controls received mp w/ vehicle; animal info (male Duncan-Hartley guinea pigs (6-month-old, weight = 600 ± 50g)); pumps replaced every 6 weeks; long-term study; dependence;
Q9514: M. A. Ulleryd, et al. RNA sequencing data describing transcriptional changes in aorta of ApoE-/- mice after alpha 7 nicotinic acetylcholine receptor (alpha7nAChR) stimulation. Data in Brief 2020;30(105415
Agents: Alpha 7 nicotinic acetylcholine receptor agonist Vehicle: Cyclodextrin; Saline; Route: SC; Species: Mice; Pump: 2004; Duration: 8 weeks;
ALZET Comments: Dose (50 μmo/kg/day); 28% cyclodextrin used; Controls received mp w/ vehicle; animal info (Male apoE-/- mice, 10 weeks old); pumps replaced every 4 weeks; Alpha 7 nicotinic acetylcholine receptor agonist aka α7nAChR agonist; gene therapy;

Agents: Cyclosporine Vehicle: Not Stated; Route: SC; Species: Rat; Pump: 2ML4; Duration: 28 days;
ALZET Comments: Dose (15 mg/ kg/d); animal info (spastic Han Wistar rat); behavioral testing (Motor Activity Testing); pumps replaced every 23 days; gene therapy;

Agents: Oxytocin Vehicle: Sodium Citrate; Route: SC; Species: Mice; Pump: 1004; Duration: 8 weeks;
ALZET Comments: Dose (4.22 ug/day); Controls received mp w/ vehicle; animal info (Male, C57BLKS/J); pumps replaced every 6 weeks; immunology;

Agents: Lipocalin-2 Vehicle: Saline; Route: SC; Species: Mice; Pump: 1002; Duration: 4 weeks;
ALZET Comments: Dose (5 μg/kg/h); Controls received mp w/ vehicle; animal info (male spontaneously hyperlipidemic Apoe−/− mice, 13 weeks old); pumps replaced every 2 weeks; Blood pressure measured via tail-cuff method;92.1 mmHg - 92.6 mmHg;Resultant plasma level (282.7 mg/dL Glucose; 27.4 pM Insulin); Lipocalin-2 aka LCN2; cardiovascular;

Agents: Glucagon Vehicle: Not Stated; Route: SC; Species: Mice; Pump: 1002; Duration: 4 weeks;
ALZET Comments: Dose (138 or 413 nmol/kg/day); Controls received mp w/ vehicle; animal info (Male ApoE-/- mice, 6 weeks old); pumps replaced every 2 weeks; Blood pressure measured via tail-cuff method;103 mmHg - 115 mmHg;Resultant plasma level (81 mg/dl Plasma glucose); diabetes;

Agents: Endorphin, B- Vehicle: Saline; Route: SC; Species: Mice; Pump: 1002; Duration: 4 weeks;
ALZET Comments: Controls received mp w/ vehicle; animal info (male spontaneously hyperlipidemic Apoe−/− mice, 13 weeks of age); pumps replaced every 2 weeks; Blood pressure measured via tail-cuff method;91.4 mmHg - 92.1 mmHg;Resultant plasma level (294.3 mg/dL Glucose); peptides; dependence;

Agents: Amyloid Beta 1-42 Vehicle: CSF, Artificial; Route: CSF/CNS; Species: Mice; Pump: 1004; Duration: 8 weeks;
ALZET Comments: Dose (10 nmol/kg/h); Controls received mp w/ vehicle; animal info (Twelve-month-old transgenic mice); pumps replaced every 4 weeks; Amyloid Beta 1-42 aka AB peptide; peptides; neurodegenerative (Alzheimer’s Disease);

Agents: Peptide, Gp91ds-tat Vehicle: Not Stated; Route: Not Stated; Species: Mice; Pump: 1004; Duration: 8 weeks;
ALZET Comments: Dose (10 mg/kg/day); animal info (Mice, 8 weeks old); pumps replaced every 4 weeks; Peptide, Gp91ds-tat aka gp91dstat; peptides; diabetes;
Agents: Angiotensin II Vehicle: Saline; Route: SC; Species: Rat; Pump: 2004; Duration: 8 weeks;
ALZET Comments: Dose (10,000 ng/kg/h); Controls received mp w/ vehicle; animal info (male Rats, 7.25 months old, 367 g); behavioral testing (Morris Water Maze, Open Field Test); pumps replaced every 4 weeks; Blood pressure measured via tail cuff method; 120 mmHg - 170 mmHg; Angiotensin II aka Ang II; cardiovascular;

Agents: Cyclosporine A Vehicle: Not Stated; Route: SC; Species: Rat; Pump: 2ML4; Duration: 4 months;
ALZET Comments: Dose (2.5 mg/kg/d); animal info (LW (RT-1l) and BN (RT-1n) rats); pumps replaced every month; Cyclosporine A aka CsA; immunology;

Agents: Beta-hydroxybutyrate Vehicle: PBS; Route: SC; Species: Mice; Pump: 1004; Duration: 8 weeks;
ALZET Comments: Dose (1.5 mmol/kg/day); Controls received mp w/ vehicle; animal info (Six-week-old male ApoE−/− and C57BL/6J mice); pumps replaced every 4 weeks; Beta-hydroxybutyrate aka B-OHB; neurodegenerative (Alzheimer’s Disease);

Agents: Salvianolic acid B Vehicle: PBS; Route: SC; Species: Mice; Pump: Not Stated; Duration: 8 weeks;
ALZET Comments: Dose (100 mg/kg/day); Controls received mp w/ vehicle; animal info (Six-week-old ApoE KO mice); pumps replaced every 4 weeks; salvianolic acid B aka SAB; neurodegenerative (Stroke);

Agents: Angiotensin II Vehicle: Saline; Route: SC; Species: Mice; Pump: 2006; Duration: 12 weeks;
ALZET Comments: Dose (1 ug/kg/min); Controls received mp w/ vehicle; animal info (3 month old male Tg mice); pumps replaced every 12 weeks; Blood pressure measured via tail-cuff; Angiotensin II aka Ang II; cardiovascular;

Agents: Olanzapine Vehicle: Saline; Route: SC; Species: Mice; Pump: Not Stated; Duration: 4 weeks;
ALZET Comments: Dose (8 mg/kg/d); Controls received mp w/ vehicle; animal info (Female C57BL/6 J mice (8 weeks old)); pumps replaced every 2 weeks; dependence;

Agents: Ibuprofen Vehicle: DMSO; PEG; Route: SC; Species: Mice; Pump: 2004; Duration: 2 months;
ALZET Comments: Dose (50 mg/kg/day); Controls received mp w/ vehicle; animal info (male C57BL/6 mice, 6 months old); pumps replaced every 28 days; dependence;

Agents: Metoprolol Vehicle: Not stated; Route: SC; Species: Mice; Pump: 1004; Duration: 3 months; 2 months;
ALZET Comments: Dose (5 mg/kg/day); Controls received mp w/ vehicle; animal info (male mice, 3.5 months old; female mice, 6 months old); behavioral testing (Morris Water Maze; Fear Conditioning); pumps replaced every 4 weeks; long-term study; neurodegenerative (Alzheimer’s);
Agents: Relaxin Vehicle: Saline; Route: IP; Species: Rat; Pump: Not stated; Duration: 12 weeks;
ALZET Comments: Dose (0.17 μg/hr); Controls received mp w/ vehicle; animal info (Sprague Dawley rats); pumps replaced every 4 weeks; long-term study; dependence;

Agents: TAT control peptide; DA1 peptide Vehicle: Not stated; Route: SC; Species: Mice; Pump: 2004; Duration: 6, 8 weeks;
ALZET Comments: Dose (1 mg/kg/day); animal info (Male, YAC128, 3 month old); behavioral testing (Tail Suspension Test); pumps replaced every 4 weeks; peptides; neurodegenerative (Huntington’s Disease);

Agents: C-type natriuretic peptide 53 Vehicle: Not Stated; Route: SC; Species: Rat; Pump: 2004; Duration: 4 weeks;
ALZET Comments: Dose (0.5 mgm/kg/day); Controls received mp w/ vehicle; animal info (CNP-KO, 5-9 weeks old); pumps replaced every 2 weeks; peptides; dependence;

Agents: dihydroxyestra-1,4-dien-3-one, 10β,17β-Vehicle: propylene glycol; Route: SC; Species: Mice; Pump: 2004; Duration: 8 weeks;
ALZET Comments: Dose (2 μg/day); Controls received sham surgery and mp w/ vehicle; animal info (6 months, female, Tg2576); behavioral testing (Morris Water Maze); pumps replaced every 4 weeks; 17beta-dihydroxyestra-1,4-diene-3-one (DHED) is a brain-selective prodrug of 17beta-estradiol; neurodegenerative (Alzheimer’s); replacement therapy (estradiol); treatment groups received bilateral ovariectomies; Therapeutic indication (hinder the progression of AD and improving cognitive functions through inhibiting klf5-NF-κB pathway and restraining oxidative and inflammatory stress in the hippocampus);

Agents: Arginine, L-homoarginine Vehicle: Not Stated; Route: SC; Species: Mice; Pump: Not Stated; Duration: 12 weeks;
ALZET Comments: Dose (0.72 mg/kg/day); animal info (6-week-old Ins2Akita mice); pumps replaced every 6 weeks; Resultant plasma level (1.4 umol/L); cardiovascular;

Agents: Ganciclovir Vehicle: Saline; Route: SC; Species: Mice; Pump: 2004; Duration: 8 weeks;
ALZET Comments: Dose (150 mg/kg/day); Controls received mp w/ vehicle; animal info (6 weeks old); pumps replaced every 4 weeks; neurodegenerative (Seizure);

Agents: Angiotensin II Vehicle: Saline; Route: SC; Species: Rat; Pump: 2ML2; Duration: 4 weeks;
ALZET Comments: Dose (555 ng/kg/min); 0.9% Saline used; Controls received mp w/ vehicle; animal info (Sprague Dawley, Male, 5-6 weeks old); pumps replaced every 2 weeks; cardiovascular;

Agents: Human chemerin; Chemerin-9 Vehicle: Saline; Route: SC; Species: Mice; Pump: 1002; Duration: 4 weeks;
ALZET Comments: Dose (human chemerin- 7.7 ug/kg/h and chemerin-9- 7.7 ug/kg/h); Controls received mp w/ vehicle; animal info (Apoe-/-, 17 weeks old, ); pumps replaced every 2 weeks; cardiovascular;
Agent: Curcumin Vehicle: DMSO; Route: SC; Species: Rat; Pump: 2ML4; Duration: 4 months;
ALZET Comments: Animal info (32 months old, Male); pumps replaced every 4 weeks; long-term study; dependence;

Agent: Legumain Vehicle: Saline; Route: SC; Species: Mice; Pump: 1002; Duration: 4 weeks;
ALZET Comments: Dose (5 ug/kg/day); Controls received mp w/ vehicle; animal info (Male, ApoE -/-, 17 weeks old); pumps replaced every 4 weeks; Blood pressure measured via Tail cuff method; cardiovascular;

Agent: Rotenone Vehicle: DMSO, Polyethylene glycol; Route: SC; Species: Rat; Pump: 2ML4; Duration: 4 weeks; 8 weeks;
ALZET Comments: Dose (1 mg/kg/day); 50% DMSO:50% PEG used; Controls received mp w/ vehicle; animal info (Male, Lewis, 8 or 9 months old); pumps replaced every 4 weeks; spinal cord injury; neurodegenerative (Motor cortex);

Agent: Hypocretin-1 Vehicle: Saline; Route: SC; Species: Mice; Pump: Not stated; Duration: 8 weeks;
ALZET Comments: Dose (50 nmol/h/kg); Controls received mp w/ vehicle; pumps replaced every 4 weeks; Hypocretin-1 aka HCRT-1; cardiovascular;

Agent: Pyridostigmine Bromide; Donepezil Vehicle: Not Stated; Route: SC; Species: Rat; Pump: 2004; Duration: 16 weeks;
ALZET Comments: Dose (Pyridostigmine bromide at 1.5 mg/kg/day; Donepezil at 1.4 mg/kg/day); animal info (5 week old male SHR and Wistar Kyoto rats); pumps replaced every 4 weeks; long-term study; enzyme inhibitor (Pyridostigmine Bromide inhibits plasma acetylcholinesterase activity; Donepezil inhibits brain acetylcholinesterase activity); cardiovascular; Four pump replacements were performed; BP measured via Tail-cuff method;

Q7616: A. Kurdi, et al. Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis. Vascul Pharmacol 2019;113(70-76
Agent: Everolimus Vehicle: DMSO; Propylene glycol; Ethanol, buffered; Route: SC; Species: Mice; Pump: 1004; Duration: 12 weeks;
ALZET Comments: "Dose (1.5 mg/kg/day); 50% DMSO, 40% propylene glycol, 10% absolute ethanol supplemented with 0.4 μl/ml Tween 20 used; animal info (6 weeks, female, ApoE(-/-)Fbnl(C1039G+/-)); pumps replaced every 4 weeks; long-term study; cardiovascular; ""Four out of 12 control animals died abruptly during the experiment, which is a phenomenon that started at 21 weeks of WD (corresponding with 9 weeks of treatment with vehicle solution)."" p.72; Therapeutic indication (stabilizes atherosclerotic plaques and reduce atherosclerosis-driven complications such as cardiac hypertrophy and fibrosis, brain hypoxia and sudden death);"

Agent: Alpha-calcitonin gene-related peptide Vehicle: Not Stated; Route: SC; Species: Mice; Pump: 1007D; Duration: 28 days;
ALZET Comments: Dose (4 mg/kg b.w/day per mouse); animal info (Eight-week-old male C57/BL6 mice); pumps replaced every 7 days; Alpha-calcitonin gene-related peptide aka a-CGRP; cardiovascular;

**Agents:** liraglutide; dorsomorphin  
**Vehicle:** Saline  
**Route:** SC  
**Species:** Mice (hyperglycemic)  
**Pump:** 1002  
**Duration:** 4 weeks  

**ALZET Comments:** Dose (liraglutide 17, 107 nmol/kg/day), (dorsomorphin 52.9 μmol/kg/day); Controls were normoglycemic and received mp w/ vehicle; animal info (20 week, male, ApoE-/-); pumps replaced every 2 weeks; liraglutide is a Glucagon-like peptide-1 receptor agonist; dorsomorphin is an enzyme inhibitor (AMPK); cardiovascular; Therapeutic indication (AMPK-independent anti-atherogenic effects through reduced lipid deposition);


**Agents:** Api137  
**Vehicle:** Saline  
**Route:** SC  
**Species:** Mice  
**Pump:** 2001D  
**Duration:** 48 hours  

**ALZET Comments:** Dose (6.4, 12.8, and 19.2 mg/kg/h); dose-response (tolerance study); 0.9% saline used; animal info (Female CD-1 mice, 18–26 g,); functionality of mp verified by residual volume; pumps replaced after 48 hours; apidaecin derivative aka Api137; peptides;


**Agents:** Murine Oncostatin M  
**Vehicle:** PBS  
**Route:** SC  
**Species:** Mice  
**Pump:** 1004  
**Duration:** 16 weeks  

**ALZET Comments:** Dose (10 or 30 μg/kg/day); Controls received mp w/ vehicle; animal info (female APOE3Leiden.CETP transgenic mice (10–15 weeks of age)); pumps replaced every 5.5 weeks; long-term study; Murine Oncostatin M aka Murine OSM; cardiovascular;


**Agents:** exenatide  
**Vehicle:** Saline, DMSO Buffered  
**Route:** SC  
**Species:** Mice  
**Pump:** Not Stated  
**Duration:** 8 weeks  

**ALZET Comments:** Dose (30μg/kg/day); 10% DMSO in saline used; Controls received mp w/ vehicle; animal info (7 weeks, male, C57BL/6); pumps replaced every 4 weeks; Exenatide (Exe) is a GLP-1 receptor agonist; pump model not stated but maximum use duration listed at 4 weeks; Therapeutic indication (may improve nonalcoholic steatohepatitis as it ameliorates mitochondrial TCA cycle flux while decreasing insulin resistance, steatosis and hepatocyte lipotoxicity);


**Agents:** Quinic acid  
**Vehicle:** Saline  
**Route:** SC  
**Species:** Mice  
**Pump:** Not stated  
**Duration:** 12 weeks  

**ALZET Comments:** Dose (75 mg/kg/day); Controls received mp w/ vehicle; animal info (12 weeks old, Male, C57BL/6N); pumps replaced every 7 weeks; Multiple pumps per animal (); long-term study; Quinic acid aka QA ; dependence;


**Agents:** Nicotine  
**Vehicle:** Saline  
**Route:** SC  
**Species:** Rat  
**Pump:** 2ML4  
**Duration:** 56 days  

**ALZET Comments:** Dose (2 mg/kg/day); Controls received mp w/ vehicle; animal info (Male, Sprague Dawley, 200-250 g); behavioral testing (Housing and behavioral test, Elevated plus maze test, Figure 8 apparatus test); pumps replaced every 4 weeks; dependence;

Q7525: C. Hartmann, et al. Angiotensin II-induced hypertension increases the mutant frequency in rat kidney. Archives of Toxicology 2019;93(7):2045-2055

**Agents:** Angiotensin II  
**Vehicle:** Saline  
**Route:** SC  
**Species:** Rat  
**Pump:** 2004, 2006  
**Duration:** 20 weeks  

**ALZET Comments:** Dose (400 ug/kg/day); Controls received mp w/ PBS; animal info (5-8 weeks old, Male); pumps replaced every 7 weeks; long-term study; cardiovascular;

**Agents:** Antifibrotic peptide acetyl-seryl-aspartyl-lysyl-proline  
**Vehicle:** Saline; **Route:** SC; **Species:** Rat; **Pump:** 2ML4; **Duration:** 8 weeks;  
**ALZET Comments:** Dose (800 mg/kg/day); 0.9% Saline used; Controls received mp w/ vehicle; animal info (Male, Wistar, 3 week sold, 80 g); pumps replaced every 4 weeks; peptides; cardiovascular.

**Agents:** Global βIIPKC inhibitor; TAT47–57-SAMβA peptide Mfn1-βIIPKC inhibitor  
**Vehicle:** Not stated; **Route:** SC; **Species:** Rat; **Pump:** Not stated; **Duration:** 6 weeks;  
**ALZET Comments:** Dose (3 mg/kg/day); animal info (Male); pumps replaced every 2 weeks; cardiovascular.

**Agents:** BX912  
**Vehicle:** DMSO; **Route:** SC; **Species:** Mice; **Pump:** 2002; **Duration:** Not stated;  
**ALZET Comments:** Dose (5 mg/kg/day); 1% used; animal info (Male, C57BL/6J, 8 weeks old); pumps replaced every 4 weeks; PDK1 inhibitor aka BX912 ; enzyme inhibitor (PDK1 inhibitor); neurodegenerative (Cruetzfeldt-Jakob, Gertsmann-Strasussler-Scheinker disease);

**Agents:** Neurotrophin-3, recomb. human  
**Vehicle:** Saline; bovine serum, albumin; **Route:** SC; **Species:** Rat; **Pump:** 2ML2; **Duration:** 4 weeks;  
**ALZET Comments:** Dose (100 μg/ml); 0.1% bovine serum albumin used; Controls received mp w/ vehicle; animal info (Lister Hooded outbred female rats, ~4 months old, 200-300g); pumps replaced every 2 weeks; ischemia (ischemic stroke); no stress (see pg. 34); Pumps made MRI compatible.

**Agents:** Small-molecule inhibitor of nuclear factor-κB signaling  
**Vehicle:** DMSO; **Route:** SC; **Species:** Mice; **Pump:** 1004; **Duration:** 8 weeks;  
**ALZET Comments:** Dose (5 mg/kg/day); Controls received mp w/ vehicle; animal info (8 weeks old); pumps replaced every 4 weeks; Small-molecule inhibitor of nuclear factor-κB signaling aka Bay 11-7082 ;

**Agents:** Nicotine  
**Vehicle:** Saline; **Route:** SC; **Species:** Rat; **Pump:** 2ML4; **Duration:** 3 months;  
**ALZET Comments:** Dose (61 mg/mL); Controls received mp w/ vehicle; animal info (adult male Sprague-Dawley rats 400-450g); pumps replaced every 4 weeks;

**Agents:** ganciclovir  
**Vehicle:** water, double distilled; **Route:** SC; **Species:** Mice; **Pump:** 2002; **Duration:** 4 weeks;  
**ALZET Comments:** Dose (100 mg/kg/d); Controls were WT and received mp w/ agent; animal info (6-8 weeks, female, C57BL/6 and NestinTK); pumps replaced every 2 weeks; neurodegenerative (multiple sclerosis);

**Agents:** Nicotinamide; Phenol Sulfate  
**Vehicle:** Not Stated; **Route:** SC; **Species:** Mice; **Pump:** 1004; **Duration:** 4 months;  
**ALZET Comments:** Dose (NAM- 30.8 mg/kg/week or 49.28 mg/kg/week); Controls received mp w/ vehicle; animal info (40-180 days old); pumps replaced every 4 weeks; Nicotinamide aka NAM ; neurodegenerative (Amyotrophic Lateral Sclerosis);

**Agents:** Tuftsin  
**Vehicle:** PBS;  
**Route:** SC;  
**Species:** Mice;  
**Pump:** Not stated;  
**Duration:** 28 days;  
**ALZET Comments:** Dose (0.25 ml/h); Controls received mp w/ vehicle; animal info (adult (8-9 weeks old and 18-20 g) female c57Bl/6 mice); pumps replaced on day 15; neurodegenerative (determine if the effect of microglia could promote the recovery of EAE and attenuate symptoms in EAE);


**Agents:** Diarylpropionitrile  
**Vehicle:** Not Stated;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** 2004;  
**Duration:** 84 days;  
**ALZET Comments:** Dose (20 μg/day); Controls received mp w/ vehicle; animal info (Female, Harlan-Wistar, 8 months old);  
  pumps replaced every 4 weeks; dependence;


**Agents:** Angiotensin II; bradykinin  
**Vehicle:** Saline;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** 2002;  
**Duration:** 14 days; 28 days;  
**ALZET Comments:** Dose (Angiotensin II (35µg/kg/d), bradykinin (0.27 mg/kg/hr; animal info (S-D rats (n = 16), aged 12 weeks, weighing 280–340 g); pumps replaced every 2 weeks; ALZET microcannula set used; cardiovascular; “Extending bradykinin-induced medullary vasodilatation over 2 weeks was even more challenging; we found that this can indeed be accomplished by chronic intramedullary infusion of Bk using implanted osmotic minipumps.” P.219


**Agents:** LNP599  
**Vehicle:** Not Stated;  
**Route:** SC;  
**Species:** Rat;  
**Pump:** 2ML4;  
**Duration:** 12 weeks;  
**ALZET Comments:** Dose (10 mg/kg/day); animal info (Male, 12 week old, Zucker); pumps replaced every 4 weeks; LNP599 aka 3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride); enzyme inhibitor (selective agonists of the sympa-tho-inhibitory I1 imidazoline receptors (LNP ligands)); cardiovascular